Ozempic and similar drugs may lower cancer risks, study finds

Ozempic and similar drugs may lower cancer risks, study finds


Breakthrough diabetes and weight loss medication may lower a patient’s risks of common cancers closely linked with obesity, a study published on Friday suggests.

Patients taking Ozempic for Type 2 diabetes management developed fewer obesity-related cancers than patients on insulin alone, according to the new study from a team of researchers at Case Western Reserve University School of Medicine.

Ozempic, along with the newer drugs Wegovy, Mounjaro, and Zepbound, all belong to the GLP-1 drug class. These have shown dramatic progress in reducing the side effects of obesity, including heart attack, stroke, and obstructive sleep apnea

Trending: Whistleblower Steps Forward, Tells Senator Why Law Enforcement Abandoned Post Before Trump Shooting

Researchers used the electronic health records for more than 1.6 million Type 2 diabetes patients for a 15 year period ending in 2018. They found patients on GLP-1 had

Continue reading


 

Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!